terlipressin has been researched along with End Stage Liver Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 6 (85.71) | 2.80 |
| Authors | Studies |
|---|---|
| Andraus, W; Arantes, RM; Carneiro-D'albuquerque, LA; Cunha, MR; De Moura, EG; Ducatti, L; Ernani, L; Fernandes, MR; Galvão, FH; Martino, RB; Nacif, LS; Pereira, PB; Pinheiro, RS; Rocha-Santos, V; Waisberg, DR | 1 |
| Angeli, P; Basso, D; Brocca, A; Burra, P; Calvino, V; Cillo, U; Cosma, C; Gagliardi, R; Gambino, C; Incicco, S; Piano, S; Stenico, M; Tonon, M; Zaninotto, M; Zeni, N | 1 |
| Arora, V; Choudhary, SP; Jindal, A; Kumar, G; Maiwall, R; Sarin, SK; Vijayaraghavan, R | 1 |
| Angus, PW; Chapman, B; Gow, PJ; Sinclair, M; Terbah, R; Testro, AG; Thwaites, PA | 1 |
| Gadano, A; Garcia-Olveira, L; Mauro, E | 1 |
| Francoz, C; Khemichian, S; Nadim, MK | 1 |
| Angeli, P; Boccagni, P; Boscato, N; Cavallin, M; Cillo, U; Fasolato, S; Gatta, A; Morando, F; Piano, S; Zanus, G | 1 |
1 review(s) available for terlipressin and End Stage Liver Disease
| Article | Year |
|---|---|
Advances in management of hepatorenal syndrome.
Topics: Acute Kidney Injury; End Stage Liver Disease; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Terlipressin | 2021 |
1 trial(s) available for terlipressin and End Stage Liver Disease
| Article | Year |
|---|---|
Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding.
Topics: End Stage Liver Disease; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Lypressin; Portal Pressure; Severity of Illness Index; Terlipressin | 2023 |
5 other study(ies) available for terlipressin and End Stage Liver Disease
| Article | Year |
|---|---|
Duodenal Necrosis and Nonvariceal Digestive Bleeding After Terlipressin Administration for Treatment of Hepatorenal Syndrome: a Case Report of a Novel Side Effect of a Commonly Used Drug.
Topics: Creatinine; End Stage Liver Disease; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatorenal Syndrome; Humans; Ischemia; Liver Cirrhosis; Lypressin; Male; Middle Aged; Necrosis; Severity of Illness Index; Terlipressin; Vasoconstrictor Agents | 2022 |
Diagnostic and prognostic performance of urinary neutrophil gelatinase-associated lipocalin in patients with cirrhosis and acute kidney injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Biomarkers; End Stage Liver Disease; Humans; Lipocalin-2; Lipocalins; Liver Cirrhosis; Prognosis; Proto-Oncogene Proteins; Severity of Illness Index; Terlipressin | 2023 |
Safety and efficacy of outpatient continuous terlipressin infusion for the treatment of portal hypertensive complications in cirrhosis.
Topics: Ascites; End Stage Liver Disease; Hepatorenal Syndrome; Humans; Hydrothorax; Liver Cirrhosis; Lypressin; Outpatients; Severity of Illness Index; Terlipressin; Treatment Outcome; Vasoconstrictor Agents | 2022 |
End-stage liver disease: Management of hepatorenal syndrome.
Topics: Acute Kidney Injury; End Stage Liver Disease; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Terlipressin; Vasoconstrictor Agents | 2021 |
Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation?
Topics: Albumins; End Stage Liver Disease; Hepatorenal Syndrome; Humans; Liver Cirrhosis, Alcoholic; Liver Transplantation; Lypressin; Male; Middle Aged; Recurrence; Terlipressin; Time Factors; Treatment Outcome; Vasoconstrictor Agents | 2011 |